Pharming Group (NASDAQ:PHAR) Sees Strong Trading Volume

Pharming Group (NASDAQ:PHAR) shares saw strong trading volume on Monday . 12,302 shares were traded during mid-day trading, an increase of 225% from the previous session’s volume of 3,784 shares.The stock last traded at $8.25 and had previously closed at $8.35.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $37.00 price objective on shares of Pharming Group in a report on Friday, May 31st.

Pharming Group Stock Down 3.6 %

The stock has a fifty day moving average price of $9.02 and a two-hundred day moving average price of $10.63.

Pharming Group (NASDAQ:PHAR) last posted its earnings results on Wednesday, May 8th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.20). Pharming Group had a negative return on equity of 4.61% and a negative net margin of 4.01%. The firm had revenue of $55.59 million during the quarter, compared to the consensus estimate of $68.43 million. On average, sell-side analysts forecast that Pharming Group will post -0.03 EPS for the current fiscal year.

Institutional Investors Weigh In On Pharming Group

An institutional investor recently bought a new stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC bought a new stake in shares of Pharming Group (NASDAQ:PHAR) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 17,710 shares of the company’s stock, valued at approximately $202,000. Hedge funds and other institutional investors own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.